{"id":29917,"date":"2025-01-07T11:23:28","date_gmt":"2025-01-07T10:23:28","guid":{"rendered":"https:\/\/ggba.swiss\/?p=29917"},"modified":"2025-01-07T11:23:29","modified_gmt":"2025-01-07T10:23:29","slug":"vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/","title":{"rendered":"Vanarix secures FDA Orphan Drug designation for its Cartibeads"},"content":{"rendered":"\n<p>Founded in 2018, <a href=\"https:\/\/www.vanarix-cartilage-regeneration.ch\/\">Vanarix<\/a> is making significant strides in regenerative medicine with its innovative Cartibeads technology. These bioengineered cartilage mini-implants use donor cartilage cells to repair articular cartilage damage, addressing a critical unmet medical need. Cartibeads are available in two forms: autologous, derived from a patient\u2019s own cells, and allogeneic, using donor cells. The latter eliminates compatibility concerns between donor and recipient while minimizing rejection risks.<\/p>\n\n\n\n<p>The implants deliver high-quality hyaline cartilage, a marked improvement over existing solutions that typically produce fibrocartilage. While the current focus is on knee treatments, Vanarix envisions broader applications for other joints, offering hope to millions affected by cartilage damage and osteoarthritis worldwide.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Promising clinical results and future plans<\/h4>\n\n\n\n<p>The FDA\u2019s <a href=\"https:\/\/www.fda.gov\/industry\/medical-products-rare-diseases-and-conditions\/designating-orphan-product-drugs-and-biological-products\">Orphan Drug Designation<\/a> for Cartibeads in the treatment of osteochondritis dissecans represents a major step forward for Vanarix. This designation provides several benefits, including tax credits for clinical trial expenses, market exclusivity upon approval, waived application fees, and access to grant funding. These incentives reduce the financial and regulatory burden, accelerating the development of treatments for rare diseases.<\/p>\n\n\n\n<p>Vanarix has already demonstrated the potential of its allogeneic Cartibeads in Phase I\/IIa clinical trials, with patients resuming intensive activity within a month of treatment. The company now aims to scale production to treat 200 patients during Phase 2 and Phase 3 trials, targeting completion by 2026\/2027.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vanarix, a Biop\u00f4le-based start-up specializing in cartilage regeneration, has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its bioengineered cartilage mini-implants, Cartibeads. <\/p>\n","protected":false},"author":6,"featured_media":29914,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[890,963,926,902],"class_list":["post-29917","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-healthcare","tag-medical-devices","tag-medtech","tag-personalized-medicine"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vanarix secures FDA Orphan Drug designation for its Cartibeads<\/title>\n<meta name=\"description\" content=\"Vanarix, a Biop\u00f4le-based start-up specializing in cartilage regeneration, has received Orphan Drug Designation (ODD) from the US FDA.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vanarix secures FDA Orphan Drug designation for its Cartibeads\" \/>\n<meta property=\"og:description\" content=\"Vanarix, a Biop\u00f4le-based start-up specializing in cartilage regeneration, has received Orphan Drug Designation (ODD) from the US FDA.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-07T10:23:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-07T10:23:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Vanarix secures FDA Orphan Drug designation for its Cartibeads\",\"datePublished\":\"2025-01-07T10:23:28+00:00\",\"dateModified\":\"2025-01-07T10:23:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/\"},\"wordCount\":228,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg\",\"keywords\":[\"Healthcare\",\"Medical Devices\",\"Medtech\",\"Personalized Medicine\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/\",\"url\":\"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/\",\"name\":\"Vanarix secures FDA Orphan Drug designation for its Cartibeads\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg\",\"datePublished\":\"2025-01-07T10:23:28+00:00\",\"dateModified\":\"2025-01-07T10:23:29+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Vanarix, a Biop\u00f4le-based start-up specializing in cartilage regeneration, has received Orphan Drug Designation (ODD) from the US FDA.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Vanarix\u2019s Cartibeads are bioengineered cartilage mini-implants designed to regenerate damaged cartilage, offering a transformative solution for articular cartilage injuries. | \u00a9 Vanarix\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vanarix secures FDA Orphan Drug designation for its Cartibeads\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vanarix secures FDA Orphan Drug designation for its Cartibeads","description":"Vanarix, a Biop\u00f4le-based start-up specializing in cartilage regeneration, has received Orphan Drug Designation (ODD) from the US FDA.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/","og_locale":"en_US","og_type":"article","og_title":"Vanarix secures FDA Orphan Drug designation for its Cartibeads","og_description":"Vanarix, a Biop\u00f4le-based start-up specializing in cartilage regeneration, has received Orphan Drug Designation (ODD) from the US FDA.","og_url":"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-01-07T10:23:28+00:00","article_modified_time":"2025-01-07T10:23:29+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Vanarix secures FDA Orphan Drug designation for its Cartibeads","datePublished":"2025-01-07T10:23:28+00:00","dateModified":"2025-01-07T10:23:29+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/"},"wordCount":228,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg","keywords":["Healthcare","Medical Devices","Medtech","Personalized Medicine"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/","url":"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/","name":"Vanarix secures FDA Orphan Drug designation for its Cartibeads","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg","datePublished":"2025-01-07T10:23:28+00:00","dateModified":"2025-01-07T10:23:29+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Vanarix, a Biop\u00f4le-based start-up specializing in cartilage regeneration, has received Orphan Drug Designation (ODD) from the US FDA.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg","width":1180,"height":811,"caption":"Vanarix\u2019s Cartibeads are bioengineered cartilage mini-implants designed to regenerate damaged cartilage, offering a transformative solution for articular cartilage injuries. | \u00a9 Vanarix"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Vanarix secures FDA Orphan Drug designation for its Cartibeads"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/29917","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=29917"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/29917\/revisions"}],"predecessor-version":[{"id":29918,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/29917\/revisions\/29918"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/29914"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=29917"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=29917"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=29917"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}